NO20072571L - Fremgangsmater for gjenfolding av rekombinante antistoffer - Google Patents

Fremgangsmater for gjenfolding av rekombinante antistoffer

Info

Publication number
NO20072571L
NO20072571L NO20072571A NO20072571A NO20072571L NO 20072571 L NO20072571 L NO 20072571L NO 20072571 A NO20072571 A NO 20072571A NO 20072571 A NO20072571 A NO 20072571A NO 20072571 L NO20072571 L NO 20072571L
Authority
NO
Norway
Prior art keywords
methods
recombinant antibodies
refolding recombinant
refolding
igg proteins
Prior art date
Application number
NO20072571A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Dillon
Douglas Rehder
Pavel Bondarenko
Margaret Ricci
Himanshu S Gadgil
Douglas Banks
Joe Zhou
Yuefeng Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072571(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20072571L publication Critical patent/NO20072571L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20072571A 2004-10-22 2007-05-21 Fremgangsmater for gjenfolding av rekombinante antistoffer NO20072571L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62129504P 2004-10-22 2004-10-22
US70176205P 2005-07-22 2005-07-22
PCT/US2005/038045 WO2006047340A2 (en) 2004-10-22 2005-10-21 Methods for refolding of recombinant antibodies

Publications (1)

Publication Number Publication Date
NO20072571L true NO20072571L (no) 2007-07-20

Family

ID=36129791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072571A NO20072571L (no) 2004-10-22 2007-05-21 Fremgangsmater for gjenfolding av rekombinante antistoffer

Country Status (16)

Country Link
US (1) US7928205B2 (ja)
EP (1) EP1805320B1 (ja)
JP (2) JP5553963B2 (ja)
KR (1) KR101370253B1 (ja)
AU (1) AU2005299716B2 (ja)
BR (1) BRPI0517457A (ja)
CA (1) CA2584211C (ja)
EA (1) EA012162B1 (ja)
IL (1) IL182626A0 (ja)
MA (1) MA29027B1 (ja)
MX (1) MX2007004437A (ja)
NO (1) NO20072571L (ja)
NZ (1) NZ554520A (ja)
RU (1) RU2007118954A (ja)
SG (1) SG156672A1 (ja)
WO (1) WO2006047340A2 (ja)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
JP5620626B2 (ja) * 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
US7476852B2 (en) * 2005-05-17 2009-01-13 Honeywell International Inc. Ionization-based detection
US8858935B2 (en) * 2005-05-19 2014-10-14 Amgen Inc. Compositions and methods for increasing the stability of antibodies
DK3056568T3 (da) * 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EP2097747A1 (en) * 2006-12-22 2009-09-09 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP4335863A3 (en) 2007-07-09 2024-07-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
CA2698809C (en) * 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
CL2008002885A1 (es) 2007-09-26 2010-07-02 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
AU2016202036B2 (en) * 2007-09-26 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
SG193868A1 (en) * 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN101939424B (zh) * 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
CN101970500B (zh) * 2008-03-12 2013-08-14 伊姆克罗尼责任有限公司 抗tyrp1抗体
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN102076355B (zh) * 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
KR20110016958A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102149825B (zh) * 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
CA2734124C (en) * 2008-08-19 2018-06-05 Otsuka Chemical Co., Ltd. Glycoprotein production method and screening method
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI544077B (zh) * 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
ES2864956T3 (es) 2009-04-30 2021-10-14 Ablynx Nv Procedimiento para la producción de anticuerpos de dominio
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
SG176074A1 (en) 2009-05-15 2011-12-29 Chugai Pharmaceutical Co Ltd Anti-axl antibody
CN102482321B (zh) 2009-06-22 2015-06-17 安姆根有限公司 使用化学控制的氧化还原态重折叠蛋白质
ES2862580T5 (es) 2009-06-25 2024-06-13 Amgen Inc Procesos de purificación por captura para proteínas expresadas en un sistema no de mamífero
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
WO2011041721A1 (en) 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
KR101930964B1 (ko) 2010-04-20 2018-12-19 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2642318C2 (ru) 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
CN104024423B (zh) * 2011-04-29 2017-03-15 拜康研究有限公司 用于降低抗体异质性的方法和产生其抗体的方法
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
SI2771364T1 (sl) * 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
AU2012347545A1 (en) * 2011-12-07 2014-06-12 Amgen Inc. IgG2 disulfide isoform separation
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
WO2013180647A1 (en) * 2012-05-31 2013-12-05 Agency For Science, Technology And Research Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014137903A2 (en) 2013-03-08 2014-09-12 Genzyme Corporation Integrated continuous manufacturing of therapeutic protein drug substances
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
JP6323447B2 (ja) * 2013-03-29 2018-05-16 株式会社大阪ソーダ 細胞培養用培地添加物
EP3030249B1 (en) * 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
WO2015150446A1 (en) 2014-04-02 2015-10-08 F. Hoffmann-La Roche Ag Method for detecting multispecific antibody light chain mispairing
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
CN107001474B (zh) 2014-11-21 2021-10-01 百时美施贵宝公司 抗cd73抗体及其用途
MX2017006323A (es) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10865253B2 (en) 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CN107108691B (zh) * 2014-12-22 2021-06-29 Ucb生物制药私人有限公司 蛋白质制造方法
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
CN115925780A (zh) * 2016-07-22 2023-04-07 美国安进公司 含有Fc的蛋白的纯化方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CA3073286A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
TW201923069A (zh) 2017-10-02 2019-06-16 美商拜耳保健有限責任公司 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法
BR112020007154A2 (pt) 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag método para produzir um polipeptídeo e polipeptídeos heterodimérico
CA3078676A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
CA3095899A1 (en) 2018-04-02 2019-10-10 Amgen Inc. Erenumab compositions and uses thereof
KR20210045425A (ko) * 2018-08-15 2021-04-26 브리스톨-마이어스 스큅 컴퍼니 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략
AU2019332764A1 (en) 2018-08-31 2021-05-06 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
WO2020077212A1 (en) * 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
KR102505383B1 (ko) 2020-03-31 2023-03-02 추가이 세이야쿠 가부시키가이샤 Dll3 표적 다중 특이성 항원 결합 분자 및 그의 사용
US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
KR20240055101A (ko) * 2021-09-14 2024-04-26 시일럼 바이오사이언시즈, 인크. 다발성 골수종의 치료 방법
WO2024147150A1 (en) * 2023-01-02 2024-07-11 Zelle Biotechnology Pvt. Ltd. Chromatographic detection, estimation and separation of amino acids in hydrolysates of monoclonal antibodies

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0293785A3 (en) 1987-05-29 1990-05-02 Oncogen Limited Partnership Cloning and expression of simian transforming growth factor-ss1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5169784A (en) * 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5266317A (en) * 1990-10-04 1993-11-30 University Of Georgia Research Foundation, Inc. Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
DE4113750A1 (de) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
ES2227513T5 (es) 1991-10-25 2009-04-01 Immunex Corporation Citoquina novedosa.
AU648214B2 (en) 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
IL109149A0 (en) * 1993-04-01 1994-06-24 Schering Corp In vitro refolding of recombinant fv fragments
AU2603995A (en) 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
EP0766564A4 (en) * 1994-06-24 1998-09-23 Immunex Corp SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
WO1996003141A1 (en) 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
DE69631331T2 (de) 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
AUPQ599700A0 (en) * 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2438094C (en) * 2001-02-23 2011-10-11 Immunex Corporation Increased recovery of active proteins
EP1492554B1 (en) 2001-06-21 2019-08-21 Althea Technologies, Inc. Spherical protein particles
JP4359503B2 (ja) * 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
EP1631314B1 (en) * 2003-06-09 2011-08-03 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
WO2005073732A2 (en) 2004-01-23 2005-08-11 Amgen Inc. Lc/ms method of analyzing high molecular weight proteins
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
EA201100177A1 (ru) * 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ

Also Published As

Publication number Publication date
EP1805320A4 (en) 2009-09-16
IL182626A0 (en) 2007-07-24
KR101370253B1 (ko) 2014-03-05
EA012162B1 (ru) 2009-08-28
AU2005299716B2 (en) 2012-09-06
JP2008520190A (ja) 2008-06-19
AU2005299716A1 (en) 2006-05-04
RU2007118954A (ru) 2008-11-27
BRPI0517457A (pt) 2008-10-07
US7928205B2 (en) 2011-04-19
CA2584211C (en) 2014-07-08
EP1805320A2 (en) 2007-07-11
US20060194280A1 (en) 2006-08-31
WO2006047340A3 (en) 2007-07-05
SG156672A1 (en) 2009-11-26
MX2007004437A (es) 2007-06-20
NZ554520A (en) 2010-03-26
MA29027B1 (fr) 2007-11-01
EA200700917A1 (ru) 2007-10-26
CA2584211A1 (en) 2006-05-04
JP5553963B2 (ja) 2014-07-23
EP1805320B1 (en) 2014-09-03
WO2006047340A2 (en) 2006-05-04
KR20070084483A (ko) 2007-08-24
JP2013055961A (ja) 2013-03-28

Similar Documents

Publication Publication Date Title
NO20072571L (no) Fremgangsmater for gjenfolding av rekombinante antistoffer
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
CY1119416T1 (el) Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
EA201590631A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
MY174493A (en) Binding agents
MX2007013759A (es) Agentes de union de esclerostina.
NZ591098A (en) Engineered anti-il-13 antibodies, compositions, methods and uses
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
WO2004065417A3 (en) Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2006134173A3 (en) Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ATE463515T1 (de) Chimaere rekombinante antigene von toxoplasma gondii
WO2007001264A3 (en) Method of making recombinant human antibodies for use in biosensor technology
NO20062081L (no) Fremgangsmate
TW200635946A (en) Binding proteins specific for human matriptase
EA201270015A1 (ru) Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
ATE417060T1 (de) Proteinallergenderivate
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
BR0215665B1 (pt) Proteína da endotoxina delta quimérica cry1ea e cry1ca
ATE516349T1 (de) Verfahren zur rückfaltung von säuger- glycosyltransferasen
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
EP2042612A3 (en) A novel nucleotide mixture for improved nucleic acid amplification performance
EA200601557A1 (ru) Уменьшение частоты спонтанных мутаций в клетках
MY145649A (en) Methods for refolding of recombinant antibodies

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS

FC2A Withdrawal, rejection or dismissal of laid open patent application